In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In-Licensing in Specialty Pharma

Executive Summary

The emerging sector of specialty pharma-companies building a business around in-licensing poorly penetrated drugs and growing their share through targeted sales efforts-represents an increasing percentage of total dealmaking volume. But could its strategy already be suffering from diminishing returns?
Advertisement

Related Content

Specialty Pharma: Eating Big Pharma's Lunch, Not Just its Leftovers?
In-Licensing in Specialty Pharma, Revisited
In-Licensing in Specialty Pharma, Revisited
Are Late-Stage Deals Driving Up the Cost of Preclinical Deals?
Are Late-Stage Deals Driving Up the Cost of Preclinical Deals?

Topics

Advertisement
UsernamePublicRestriction

Register

IV002203

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel